Scholar Rock slides as Q1 results highlight apitegromab BLA acceptance and site reinspection
Scholar Rock reported Q1 2026 results today and said the FDA accepted its apitegromab BLA for SMA with a Sept. 30, 2026 PDUFA action date. The company also said the FDA completed a reinspection of the Catalent Indiana fill-finish site, with a facility classification expected within 90 days.
1. What happened today (May 7, 2026)
Scholar Rock disclosed first-quarter 2026 financial results and business updates today, alongside an FDA regulatory update on its lead program apitegromab in spinal muscular atrophy.
2. The concrete catalyst
The company said the FDA accepted the apitegromab Biologics License Application for SMA and set a Prescription Drug User Fee Act action date of September 30, 2026. It also said the FDA completed a reinspection of the Catalent Indiana fill-finish facility, with a facility classification expected within 90 days after the reinspection.
3. Why the stock could be down despite the update
With the BLA acceptance now formalized, trading focus can shift to manufacturing-site outcomes and timing risk (the forthcoming facility classification) as well as near-term financial burn details from the quarter. A modest pullback can occur if investors were already positioned for the acceptance or if quarterly loss/cash-use headlines were viewed as less favorable.